Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors

Phase 1 Recruiting 493 enrolled Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

NaSequentialOpen-labelTreatment

Summary

This is a phase 1 multi-center, open-label study evaluating IBI3028 Treatment in participants with locally advanced, unresectable, or metastatic solid tumors

Timeline

Start: 2026-03-31
Primary completion: 2027-06-30
Completion: 2028-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IBI3028	Unknown	—	—

Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors

Summary

Timeline

Drugs

Indications